Tag: chronic venous insufficiency
Positive one-year data for new venous valve portends promising future in...
SAVVE trial principal investigators discuss results showing 98.4% VenoValve device patency, 85% clinically meaningful benefit and an 80% rate of ulcer size reduction at...
One-year data from VenoValve US pivotal trial emerges
Envveno Medical has announced that it will present one-year data on all patients from the VenoValve US pivotal trial today at the VEITHsymposium (19–23 November, New York,...
PMA application submitted for VenoValve device
enVVeno Medical today announced it has submitted an application with the U.S. Food and Drug Administration (FDA) seeking approval to market the VenoValve—a surgical...
Bioprosthetic venous valve imparts sustained clinical improvement at one year regardless...
A new paper that drills into the impact of a novel bioprosthetic venous valve replacement by CEAP (Clinical, Etiological, Anatomical and Pathophysiological) classification shows...
Eastern Vascular Society set to stage day of service during 2024...
The Eastern Vascular Society (EVS) has incorporated a day of service into its 2024 annual meeting, being held in Charleston, South Carolina (Sept. 19–22).
Leading...
Prosthetic valve implantation shows “vast” improvements in deep chronic venous insufficiency
“The surgical challenges of repairing deep venous reflux have been present for more than a generation. It is worth reflecting on the fact that...
Less vain and more vein: Evaluating the perceptions of venous disease...
Our biases permeate the fabric of our very being, as they weave their way into our training and practice. It is clear that complex...
Cook Medical treats first patient in first-in-human clinical trial for venous...
Cook Medical recently announced that the first patient has been treated in a clinical study to evaluate a new venous valve designed for treating...
Bioprosthetic venous valve: ‘We want to know that this is really...
A key investigator in efforts to tackle chronic venous insufficiency (CVI) with an bioprosthetic venous valve replacement talks about progress being made with surgical...
AVF 2023: Investigators report update on three-year first-in-human results for bioprosthetic...
Researchers in Colombia behind the first-in-human study of a novel bioprosthetic venous valve designed to treat chronic venous insufficiency (CVI) reported three-year results among...
First-in-human patients continue to benefit from VenoValve at average of three...
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...
AVF 2022: Emerging autogenous venous valve formation system sees ‘continual improvement’
An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual...
AVF 2022: VenoValve improvement ‘maintained’ for 2.5 years without adverse events
Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum (AVF)...
VIVID study on Duo venous stent system now fully enrolled, Vesper...
Vesper Medical recently announced the completion of enrollment in its pivotal study—VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper Duo venous stent...
Envveno Medical reports successful completion of first VenoValve surgery in US...
Envveno Medical—formerly Hancock Jaffe Laboratories—recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has been successfully...
Colombian researchers report positive 24-month results for VenoValve
Promising two-year results for an emerging potential prosthetic venous valve replacement—which is about to commence a U.S. pivotal trial—were announced at the Vascular Annual...
VenoValve granted FDA Breakthrough Device designation
Hancock Jaffe Laboratories today (Wednesday, Aug. 4) announced that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the company's...
VenoValve: Chronic venous insufficiency device gains brisk double of first US...
Hancock Jaffe Laboratories recently revealed that the United States Patent and Trademark Office (USPTO) issued the first patent covering the company’s VenoValve. The patent is...
VenaSeal superior for management of chronic venous insufficiency, finds systematic review
According to a network meta-analysis, the VenaSeal system by Medtronic is “a promising therapeutic option for anatomic success at six months.” The study, published...